Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DURHAM, N.C., March 08, 2018 -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Cowen 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 10:40 a.m. ET in Boston, Massachusetts.
A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been accepted for priority review by FDA for this initial indication with a PDUFA goal date of May 21, 2018.
Contacts
Mark W. Hahn
(919) 338-7936
[email protected]
Westwicke Partners
John Woolford
(443) 213-0506
[email protected]
